 Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results Plan to Meet with Regulatory Authorities to Determine Next Steps NEW YORK, Dec. 01, 2022 GLOBE NEWSWIRE Anavex Life Sciences Corp. Anavex or the Company Nasdaq: AVXL, ... The post ANAVEX273 Blarcamesine Phase 2B3 Study Met Primary and Key Secondary Endpoi... 